{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-234882","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2026-05-21T21:12:40+00:00","discovered_at":"2026-05-21T21:14:00.337248+00:00","generated_at":"2026-05-21T21:16:41.357067+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"confidence":"high","headline":"Sensei Biotherapeutics schedules June 10 vote on Series B conversion that would trigger change of control","bullets":["Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.","Conversion would issue ~24.4M shares, representing >20% of outstanding and result in change of control per Nasdaq rules.","Pro forma shows reclassification of $321.9M from preferred stock to equity; net loss per share improves from $131.45 to $6.62.","Conversion contingent on stockholder approval; if approved, occurs three business days after vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-234882","json":"https://secwatch.observer/filing/0001193125-26-234882.json","markdown":"https://secwatch.observer/filing/0001193125-26-234882.md","text":"https://secwatch.observer/filing/0001193125-26-234882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/0001193125-26-234882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526234882/d162035d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T21:16:41.357067+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}